Showing 6181-6190 of 9536 results for "".
- Phase 3 Trials launching for adalimumab for hidradenitis suppurativahttps://practicaldermatology.com/news/20120315-phase_3_trials_launching_for_adalimumab_for_hidradenitis_suppurativa/2459842/Two Phase 3 clinical trials are underway to evaluate the safety and efficacy of Abbott's Humira (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS). The
- Merz Clarifies Status of Xeomin, Appoints William (Bill) Humphries CEOhttps://practicaldermatology.com/news/20120314-merz_clarifies_status_of_xeomin_appoints_new_ceo/2459845/Following a hearing in US District Court yesterday, Merz, Inc. is clarifying the availability of Xeomin and has appointed William (Bill) D. Humphries as CEO of Merz Inc., effective March 15. Merz Pharmaceuticals, LLC will continue to sell Xeomin fo
- Syneron to Acquire TransPharma Medicalhttps://practicaldermatology.com/news/20120313-syneron_to_acquire_transpharma_medical/2459847/Syneron Medical Ltd. (NASDAQ: ELOS) has signed a definitive agreement to acquire substantially all the assets of TransPharma Medical Ltd. TransPharma Medical, a specialty pharmaceutical company focused on the development and commercialization of drug-
- Onset Launches Aurstat Kithttps://practicaldermatology.com/news/20120302-onset_launches_aurstat_kit/2459855/The Aurstat Kit (Onset Dermatologics) containing Aurstat Skin and Wound Hydrogel and HylatopicPlus Cream is now available. Aurstat is an easy to use topical formulation, the company says. HylatopicPlus is a ceramide-rich, non-steroidal prescription t
- Health Care Fraud Prevention and Enforcement Efforts Net Nearly $4.1Bhttps://practicaldermatology.com/news/20120302-health_care_fraud_prevention_and_enforcement_efforts_net_nearly_41b/2459856/Attorney General Eric Holder and Department of Health and Human Services (HHS) Secretary Kathleen Sebelius today released a new report showing that the government's health care fraud prevention and enforcement efforts recovered nearly $4.1 billion in taxpayer dollars in Fiscal Year (FY) 2011. This
- National Academy of Dermatology Nurse Practitioners Inaugural Conference in Mayhttps://practicaldermatology.com/news/20120224-national_academy_of_dermatology_nurse_practitioners__inaugural_conference_in_may/2459865/The inaugural conference of the National Academy of Dermatology Nurse Practitioners will be held May 2-5, 2012 in Clearwater Beach, FL at the Sheraton Sand Key Resort. Designed for all nurse practitioners regardless of experience or practice seting, the program covers both medical and aesthetic derm
- Early Data Presented for Celotres™ for Keloid Scarshttps://practicaldermatology.com/news/20120224-early_data_presented_for_celotres_for_keloid_scars/2459866/Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment o
- Ulthera to Expand Operationshttps://practicaldermatology.com/news/20120210-ulthera_to_expand_operations/2459868/Ulthera, Inc. (www.ultherapy.com) is expanding its operations to include the manufacturing of various components of its technology, part of a growth plan anticipated to create more than 100 new, high-wage jobs and result in $1.68 milli
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://practicaldermatology.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF
- Discrimination, Language Gaps Undermine HS Care for Latine Adults: Analysishttps://practicaldermatology.com/news/latine-patients-with-hs-face-barriers-in-pain-and-wound-care-study-finds-discrimination-language-gaps-undermine-hs-care-for-latine-adults/2485130/Latine patients with hidradenitis suppurativa (HS) continue to face barriers to care, according to a qualitative study published in JAMA Dermatology. Study researchers analyzed transcripts from semistructured interviews